Oncolytic virotherapies, including the modied herpes simplex virus talimogene laherparepvec (T-VEC), have shown great promise as potent instigators of anti-tumour immune eects. The OPTiM trial in particular demonstrated the superior anti-cancer eects of T-VEC as compared to more traditional immunotherapy treatment using exogenous administration of granulocyte-macrophage colony-stimulating factor (GM-CSF). Theoretically, a combined approach leveraging immunotherapies like exogenous cytokine administration and oncolytic virotherapy would elicit an even greater immune response and improve patient outcomes, but given that their ecacy and safety must be tested in large clinical trials, combination therapeutic regimens have yet to be established. By adopting computational biology and in silico clinical trial approaches, here we show signicantly improved patient outcomes for individuals with late-stage melanoma by personalizing and optimizing combination oncolytic virotherapy and GM-CSF therapy. Our results serve as a proof-of-concept for interdisciplinary approaches to determining combination therapy, and suggest promising avenues of investigation towards tailored combination immunotherapy/oncolytic virotherapy.
Introduction
Modern cancer treatments increasingly incorporate a broad class of biological therapies known as immunotherapies to activate the immune system against cancer cells in a generalized or targeted way.
1, 2 These therapies seek to exploit existing tumour-immune interactions to more eciently and eectively recognize and destroy tumour cells while hopefully minimizing o-target and detrimental side eects. Current and investigational immunotherapies include immune-checkpoint inhibitors, monoclonal antibodies, CAR-T cells, and the exogenous administration of cytokines. One such cytokine, granulocyte-macrophage colonystimulating factor (GM-CSF), is a white blood cell growth factor responsible for stimulating granulocyte production, and orchestrating innate inammatory responses. GM-CSF has been used to increase the ecacy of monoclonal antibodies, and has also been administered during B-cell lymphoma treatment to activate certain immune cell subsets.
2
Another older idea, more recently explored, is to use oncolytic viruses to destroy tumour cells 3, 4 and activate an immune response. These oncolytic viruses are genetically engineered to preferentially attack and infect cancerous cells, 5, 6 forcing them to undergo lysis and release tumour specic antigens that signal the immune system to mount an anti-tumour response.
7, 8
This double eect against tumour cells has motivated the study of oncolytic viruses as a treatment against a variety of malignant solid tumours, and the modied herpes simplex virus talimogene laherparepvec (T-VEC) was approved for use in patients with non-resectable melanoma in 2015.
911 T-VEC is specically engineered to enhance expression of GM-CSF after viral infection into tumour cells.
9 However, despite much promise, the ecacy of oncolytic virus monotherapy has been limited. 8, 12, 13 As it is reasonable to expect that immunotherapy and virotherapy could act synergistically to instigate an immune response against tumour cells, 1416 recent eorts have focused on determining the anticipated benet to their use in combination with a variety of immunotherapies. 17, 18 To that end, GM-CSF has been considered as an immune stimulant during oncolytic virotherapy. 1921 To that end, here we detail a rational, quantitative approach to therapy scheduling and optimization of combination immuno-oncolytic virotherapy for patients with late stage melanoma using an in silico clinical trial.
By generating identical virtual patient cohorts, we determined optimal, individualized treatment regimens for combined GM-CSF immunotherapy and oncolytic virotherapy through in silico clinical trial simulations. These individualized schedules served to determine an optimal dosing scheme that signicantly improves overall survival while substantially reducing drug burden, highlighting the potential and potency of rational regimen prediction using a computational biology approach.
Materials and Methods

Computational Biology Model
To investigate the synergy between immunotherapy (exogenous GM-CSF) and oncolytic virotherapy, we adapted our previous mathematical model 22 describing the instantaneous change in tumour size, phagocyte numbers and cytokine concentrations over time, with and without therapy. The model tracks both immuno-susceptible and immuno-resistant tumour cell populations as they transit through the cell cycle. Quiescent immuno-susceptible tumour cells can be cleared through either random death or immune pressure, or transit into the G 1 phase to begin division. Cells in G 1 are also subject to random death and immune clearance before beginning the mitotic process. After completing division, susceptible cells return to quiescence. Mitotic cells may mutate at rate µ into an immuno-resistant cell type with a low probability. This immuno-resistant lineage maintains the same cell cycle behaviour of non-resistant tumour cells, but, as it evades immune pressure, is not subject to any immune interactions. We do not distinguish between dierent types of immune cells in the tumour microenvironment, but rather model all phagocytes as a single population.
These phagocytes interact with the susceptible tumour cell population and produce a proinammatory cytokine (e.g. interleukin-12, tumour necrosis factor, interferon gamma, GM-CSF etc.) to recruit other phagocytes to the tumour site. Model predictions are obtained by simulation, as previously described 22 (full details are provided in the Supplementary Information). The various interactions described above are schematized in Figure 1 .
Generation of In Silico Individuals and Patient Cohorts
In our previous work, the growth of a malignant tumour was parameterized using average values representative of an average patient.
22 However, as patient populations are heterogenous, our mathematical model must be adapted to reect this reality. Accordingly, we individualized the model by generating a unique set of parameters to represent individuals as potential participants in the virtual trial. We sampled from a generated normal distribution with mean as previously given 22 and with realistic standard deviations about this mean.
Mathematically, we considered p to be the vector of average parameter values from our previous model. 22 Each individual is then generated by sampling from a normal distribution with mean µ = p and standard deviation σ = 16.33%, so that 99.7% of values fall within the interval [µ − 3σ, µ + 3σ] = [0.5p, 1.5p].
To mimic real clinical trials, we imposed selection and inclusion criteria on each generated individual by verifying that each patient responds in a physiologically-realistic way without and with treatment.
19 For this, we compared the predicted response of each virtual patient to currently approved oncolytic virotherapy for stage IIIb or IV non-surgically resectable melanoma. We accepted a total of 200 virtual patients, generated by the parameter sampling and selection processes outlined above. Each virtual patient was then reproduced into n identical clones, and each resulting clone was subsequently assigned to one of n separate cohorts (for example, a treatment free control group, a mono-immunotherapy group, and an oncolytic virotherapy group, for a total of n = 3 cohorts). In this way, the total number of participants 
22
The model was then simulated for each individual and tumour growth predictions (tumour doubling time) were tested for physiological relevance. If the in silico patient's tumour growth behaviour was considered physiologically realistic, they were cloned n times and each clone was assigned to n separate arms of the in silico clinical trial.
Recapitulation of Previous Trial Data
Using three identical cohorts, we evaluated patient outcomes when they received no treatment (Cohort 1), immunotherapy (Cohort 2), or oncolytic virus monotherapy (Cohort 3).
This setup mimics that of the T-VEC OPTiM trial, where individuals were randomized to receive either intralesional T-VEC or subcutaneous GM-CSF.
9
In both the in silico immunotherapy and oncolytic virus monotherapy cases, the dosing schedules were identical to the ones used in the OPTiM trial:
9 patients in the T-VEC arm received a priming dose of 10 6 plaque forming units pfu/mL, followed by 10 Tolerability of combined therapy was attained by bounding the permissible dose size to be four times the standard dose amount. As it is only possible to administer discrete amounts of a drug, typically limited to be some multiple of the available vial size, we constrained the dose size to be 1 − 4-times the standard dose size for both immunotherapy and virotherapy. We 9
To study whether denser treatment scheduling improved clinical outcomes, we allowed for increased treatment frequency, under the constraint that the cumulative dose administered in the optimal treatment regimen must be less than the cumulative dose administered during the OPTiM trial.
Genetic algorithms are heuristic global optimization routines inspired by natural selection 2729 that are frequently employed to estimate parameters in computational biology models. They have also previously been applied to study optimal dosing routines in immunology.
29 To determine personalized dosing regimens, the optimal function F (Dose) was minimized over a ten-week treatment period using Matlab's genetic algorithm function ga.
30
We then generated personalized schedules for each of the 200 individuals in the optimal combination cohort. These schedules determined an underlying statistical distribution of the likelihood of administering a dose of either immuno-or virotherapy on a given day of the treatment period. Sampling from this empirical distribution, we next determined P I (Day i ) and P V (Day i ), or the probability that immunotherapy or virotherapy, respectively, is administered on Day i of therapy. These probabilities served to determine an optimal treatment schedule at the population-level.
Inference and Validation of Optimal Treatment Schedule
We rst determined whether a dose of immunotherapy was to be administered on the i-th day of treatment by ipping a coin based on the probability of administering immunotherapy. This is mathematically equivalent to sampling from a Bernoulli distribution with probability given by P I (Day i ) (see Table 1 ). If a dose was administered, we sampled from the empirical distribution of dose sizes determined from the individualization (see previous section) with weights P I (n|Day i ) (i.e. the probability of giving a dose of size n given that immunotherapy is administered on day i) to determine the size of the immunotherapy size. If the i-th day is the beginning of a new treatment cycle, virotherapy may be administered. If so, the same series of steps determined whether virotherapy was administered, and if so, the size of dose,
To test the eectiveness of the optimal dosing schedule, we created and cloned 100 new virtual patients, and separated them into three three trial arms. The rst cohort received the combined immuno-and virotherapy of 125 µg/m 2 of GM-CSF daily for 14 days in 28 day cycles and 1 dose of virotherapy every 14 days 9 (standard-of-care). A maintenance therapy schedule was followed for the second cohort (see Results). Finally, the dosing regimens determined from the population optimization were applied to the third arm. Mortality and removal from the trial followed the same procedure described in the Model Calibration section above.
Local Sensitivity Analysis
Potential drug targets were identied by performing a sensitivity analysis on the mathemat- 
Results
Computational Biology Model Successfully Predicts Existing Therapy Results
We rst compared the model predictions to the OPTiM results 9 to evaluate the computational biology model's ability to accurately represent the outcomes for patients receiving either GM-CSF or the oncolytic virus monotherapy T-VEC. 
9
All or Nothing Virotherapy Dosing Strategy
We expected that treatment with GM-CSF would be used to either prime the immune system before virotherapy, or to support the immune response directly following administration of the oncolytic virus. However, as seen in Fig. 4 , no structure is easily discerned. To better understand the underlying distribution structure of the individualized treatment schedules, we calculated the probability that any immunotherapy should be administered on each of the seven treatment cycle days of the optimized therapy regimen, as described in the Methods section (Optimization Routine for Combined Immuno-and Oncolytic Virotherapy). If a dose was given, we computed the conditional probability of administering a dose of one, two, three or four multiples of the standard dose. We found that the probability of administering a dose of immunotherapy for a given treatment day is roughly constant at 25% throughout the treatment cycle. Interestingly, our results indicate that the immunotherapy dose given is expected to be either the smallest or the largest permitted (see Tab. 1), suggesting that immunotherapy is most useful as an additional instigator when virotherapy does not elicit a sucient immune response, or to otherwise maintain the immune recruitment initiated by successful viral infection and lysis. Table 1 : The probability of administering immunotherapy (P I (A)) in each day of the treatment cycle and the conditional probability (P I (n|A) of administering n doses of immunotherapy for n = 1, 2, 3, 4.
Contrary to the mono-immunotherapy dosing schedule, the conditional probabilities P V (Day i )
in the viral oncology case (see Tab. 2) are heavily skewed to the maximal tolerable dose.
Given the mechanism of action of virotherapy (namely, infecting tumour cells), it is unsurprising that administering a larger dose of oncolytic virus should improve clinical outcomes.
Put dierently, an all or nothing approach of dosing infrequently, but for maximal therapeutic benet, is optimal, in contrast to the logic of the immunotherapy case.
These results suggest that administering immunotherapy between administrations of virotherapy serves mainly to maintain immune recruitment. of immunotherapy were therefore administered on days 3, 6, 9, and 12 to replicate the total expected immunotherapy dose. The same procedure was used to determine the virotherapy dose. Table 2 : Conditional probabilities for oncolytic virotherapy administration inferred from individualized dose schedule optimization. The probability of administering virotherapy on each 7th day of the treatment cycle (P V (Day 7 )) and the conditional probability P V (n|Day 7 ) of administering n doses of virotherapy for n = 1, 2, 3, 4.
Local Sensitivity Establishes Previously-Identied and Potential Therapeutic Targets
The parameters controlling the dynamics of mitotic cells are the most sensitive, with the 10% change accounting for drastic changes in disease burden. For example, increasing the rate at which G 1 cells enter into mitosis results in a 11-fold increase in tumour burden, while decreasing this rate decreases the tumour burden by a factor of 33. This indicates that interventions that inhibit the specic transition from G 1 into mitosis oer therapeutic benets. Figure 5 shows the percent change in tumour doubling time and tumour burden corresponding to each parameter. Mean survival times between patients receiving the maintenance therapy and the inferred optimal therapy were not signicantly dierent (42.8 months vs 43.2 months, two-sided t-test p-value of 0.62). This is not unsurprising, given that the maintenance therapy was dened directly from the personalized regimens using the naïve constraint that immunotherapy be equally spread out throughout each virotherapy cycle. This restriction was imposed after observing that the probability of administering immunotherapy on a given day i of the treatment cycle (P I (Day i )) is more or less equal across our 200 in silico individuals. In both cases, the individualization routine was leveraged to create clinically actionable therapeutic strategies. However, as the optimal regimen additionally reduces the overall drug burden during each virotherapy cycle, it could still be considered more optimal than the maintenance strategy, despite the insignicant dierence in mean survival time between the two regimens.
In summary, in terms of both end-points and patient burden (dened as the number of treatment days per cycle), immune maintenance therapy outperforms the standard-of-care combination therapy, both of which are improved upon by the optimal dosing schedule. The lack of signicant dierence between mean survival times in the maintenance and optimal schedules also further motivates the use of in silico clinical trial generation as a means to propose candidate investigational regimens prior to clinical trial enrolment.
Discussion
Improving patient end-points and decreasing the drug burden during anti-cancer treatment are crucial components of cancer care. The introduction of new and advanced therapy modalities is critical to this goal. The approval of T-VEC, the rst genetically modied oncolytic virus, was an important step forward for the treatment of late-stage melanoma that signicantly improved patient survival over mono-immunotherapy GM-CSF administration.
However, the question of whether combined immunotherapy and virotherapy will provide further benets for patients and, if so, the optimal strategy for such combination therapy, remains. Running clinical trials is an expensive and onerous process. Trial failures are disappointing for patients, clinicians, and researchers, and contribute to overall attrition along the drug development pipeline. Here we have outlined a rational approach to therapy optimization that has signicant consequences for how we eectively design and implement clinical trials to maximize their success, and how we treat melanoma with combined immuno-
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Time (months) Let Q(t) and G 1 (t) denote the quiescent and proliferative phase susceptible tumour cells, respectively, and Q R (t), G 1,R (t) the similar immune-resistant cells. To account for immune selection, we included a resistant strain of tumour cells that are undetectable to the immune system. We assumed that tumour cells successfully completing mitosis can randomly mutate into the immune resistant strain with probability µ = 1 × 10 −10 , and we assume that the mutated strain of cancer cells reproduce in an identical manner to the non-mutated strain.
The cytokine concentration is denoted by C(t), and the phagocyte concentration in the tumour microenvironment by P (t). Finally, V (t) is the concentration of oncolytic virions and I(t) is the number of infected tumour cells. Susceptible tumour cells are infected at a rate η while tumour-immune interaction occurs at the rate ψ Q,G . 
The dierential equations describing the progression of disease are
The total number of cells in the cell cycle is given by
and the parameters used to dene the average patient in the section Generation of In Silico Individuals and Patient Cohorts in the main text are given in Table S1 . These parameters are the same as previously reported.
22
We model the subcutaneous administration of N doses of GM-CSF similar to Craig et al.
33
Dose
where the amount of GM-CSF administered at time t i is Dose As we consider intralesional administration, the entire dose of oncolytic virus is bioavailable, so F V = 1 and absorption into the tumour is much faster than cytokine absorption, so k v a >> k c a . Equation (S2) is simulated using its nite dimensional representation.
22
Simulation of the Mathematical Model
Cassidy and Humphries 22 demonstrated how to reduce the mathematical model (S2) without mutation to a resistant lineage to a nite dimensional system of ordinary dierential equations (ODE) when K(t) is the probability density function of the gamma distribution, g j ktr (t). Using an identical technique, the nite dimensional system of ODEs corresponding 
The system in Eq. (S5) is simulated using the sti ODE solver ode 15s. 30 
